Uncover key drivers, emerging technologies, and competitive movements shaping the worker heat stress monitoring wearable market from 2026–2035 with trusted insights from The Business Research Company
What level of CAGR-driven expansion is anticipated in the Positron Emission Tomography (PET) Radiotracer Market between 2026 and 2030?
The positron emission tomography (pet) radiotracer market has shown significant expansion over recent years. Its valuation is anticipated to increase from $2.54 billion in 2025 to $2.78 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.2%. In the past, this growth was primarily influenced by a rise in cancer diagnosis rates, an increase in nuclear medicine facilities, the widespread adoption of FDG-based imaging, the availability of cyclotron infrastructure, and the expansion of diagnostic imaging services.
The positron emission tomography (pet) radiotracer market is projected to experience robust expansion in the upcoming years. This market is forecast to reach a valuation of $3.95 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.2%. Factors contributing to this anticipated growth include a heightened demand for precision diagnostics, increased investments in radiopharmaceutical research and development, the broadening scope of theranostics applications, the expanding use of pet imaging in neurology and cardiology, and a rise in regulatory clearances for novel tracers. Key trends foreseen during this period involve the intensified creation of target-specific radiotracers, the increasing integration of pet imaging in oncology diagnostics, the wider utilization of new isotopes beyond FDG, the proliferation of personalized nuclear medicine applications, and a stronger emphasis on producing short-half-life radiotracers.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19152&type=smp
What Drivers Are Affecting Demand-Supply Dynamics In The Positron Emission Tomography (PET) Radiotracer Market?
A rise in infectious diseases is anticipated to boost the expansion of the positron emission tomography (PET) radiotracer market in the future. These diseases are defined as ailments resulting from pathogenic microorganisms like bacteria, viruses, fungi, or parasites. The growing occurrence of infectious diseases stems from factors such as climate change, urbanization, globalization, antibiotic resistance, and shifts in human behavior, all of which aid pathogen dissemination. Positron emission tomography (PET) radiotracers assist in managing infectious diseases by allowing visualization of metabolic activity and inflammation, thereby facilitating infection detection, evaluating treatment efficacy, and distinguishing between infectious and non-infectious conditions to improve patient results. For example, a report from the UK Health Security Agency, a UK-based government body, indicated in February 2024 that tuberculosis (TB) incidents in England saw a 10.7% rise in 2023, reporting 4,850 cases versus 4,380 in 2022. Consequently, the increasing prevalence of infectious diseases is acting as a catalyst for the expansion of the positron emission tomography (PET) radiotracer market.
How Is The Positron Emission Tomography (PET) Radiotracer Market Organized Into Various Segments?
The positron emission tomography (pet) radiotracer market covered in this report is segmented –
1) By Radiotracer Type: F-18 (Fluorodeoxyglucose 18), Ga-68 (Fibroblast Activation Protein Inhibitor), Other Radiotracer Types
2) By Application: Cancer, Heart Disease, Gastrointestinal, Endocrine, Neurological Disorders, Other Applications
3) By End-User: Hospitals, Diagnostic Centers, Other End-Users
Subsegments:
1) By F-18 (Fluorodeoxyglucose 18): F-18 FDG (Fluorodeoxyglucose), F-18 Fluoroethyltyrosine (FET), F-18 Florbetapir (Amyloid PET Imaging)
2) By Ga-68 (Fibroblast Activation Protein Inhibitor): Ga-68 Dotatate (Neuroendocrine Tumor Imaging), Ga-68 PSMA (Prostate-Specific Membrane Antigen Imaging), Ga-68 FAPI (Fibroblast Activation Protein Inhibitor Imaging)
3) By Other Radiotracer Types: C-11 (Carbon-11), N-13 (Nitrogen-13), O-15 (Oxygen-15), Rb-82 (Rubidium-82), I-124 (Iodine-124)
Which Trends Are Guiding The Evolution Of The Positron Emission Tomography (PET) Radiotracer Market?
Major companies within the positron emission tomography (PET) radiotracer market are concentrating on developing advanced diagnostic solutions, such as positron emission tomography imaging agents, to improve cancer detection and enhance patient outcomes. A positron emission tomography (PET) imaging agent is a radioactive substance utilized to visualize and measure biological processes within the body during PET scans. For instance, in March 2023, IsoLogic Innovative Radiopharmaceuticals, a Canada-based radiopharmaceutical company, launched Illuccix, also known as the Ga-68 Gozetotide Preparation Kit (PSMA-11), in Canada. This agent is designed for prostate cancer imaging to detect metastatic prostate cancer. This tool proves valuable for physicians in identifying metastatic disease and guiding patient management decisions. Its use is indicated for patients suspected of having metastasis who are suitable for initial definitive therapy, and also for those with suspected recurrence as indicated by elevated serum prostate-specific antigen (PSA) levels.
Who Are The Top-Performing Companies In The Positron Emission Tomography (PET) Radiotracer Market In Recent Years?
Major companies operating in the positron emission tomography (pet) radiotracer market are Cardinal Health Inc., GE Healthcare Technologies Inc., Bracco Imaging S.p.A., Lantheus Holdings Inc., Jubilant Pharma Limited, SOFIE Biosciences, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Nordion Inc., Isologic Innovative Radiopharmaceuticals, ABX Advanced Biochemical Compounds GmbH, IBA Radiopharma Solutions S.A., ImaginAb Inc., Radiomedix Inc., Curium Pharma, Blue Earth Diagnostics Ltd., Eckert & Ziegler Radiopharma GmbH, Advanced Accelerator Applications (Novartis), Telix Pharmaceuticals Limited, PETNET Solutions Inc., Piramal Imaging
Access The Complete Report For Deeper Market Insights:
How Does The Positron Emission Tomography (PET) Radiotracer Market Perform Across Major Global Regions?
North America was the largest region in the positron emission tomography (PET) radiotracer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the positron emission tomography (pet) radiotracer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Positron Emission Tomography (PET) Radiotracer Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=19152&type=smp
Browse Through More Reports Similar to the Global Positron Emission Tomography (PET) Radiotracer Market 2026, By The Business Research Company
Poc Medical Imaging Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/poc-medical-imaging-global-market-report
Veterinary Imaging Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/veterinary-imaging-global-market-report
Pet Tech Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/pet-tech-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company